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A B S T R A C T
The antimicrobial susceptibility patterns of 73
glycopeptide-resistant Enterococcus faecalis isolates
from nine hospitals in Brazil were analysed by the
disk diffusion method and Etests. Isolates were
typed by pulsed-field gel electrophoresis (PFGE),
and vancomycin resistance genes were detected
by PCR. The isolates shared a single major PFGE
pattern, with six subtypes, and all were positive
for vanA. These results indicate the occurrence of
inter-hospital dissemination of glycopeptide-
resistant E. faecalis in Sa˜o Paulo, and raise con-
cerns about the rapid dissemination of this
pathogen throughout Brazil.
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Enterococci have been isolated with increasing
frequency from nosocomial infections over the
past two decades. These opportunistic pathogens
represent a frequent cause of infection in patients
hospitalised for long periods or in patients receiv-
ing multiple courses of antimicrobial therapy [1].
The percentage of nosocomial infections in the
USA caused by glycopeptide-resistant enterococci
(GRE) increased from 0.3% in 1989 to 25.9% in
1999 [2]. The SENTRY Antimicrobial Surveillance
Program identified an increase in the prevalence
of glycopeptide resistance among clinical isolates
of enterococci in the USA and Latin America,
from 14% and 0% in 1997, to 17% and 2% in
1999, respectively [3].
There are important differences in the epidemi-
ology of GRE in the USA and Europe [4,5]. In the
USA, the high incidence of infections with GRE has
been attributed to the extensive use of vancomycin
in hospitals [6]. In contrast, infections with GRE
and outbreaks occur less frequently in most west-
ern European countries, although GRE have been
identified among healthy individuals, as well as in
raw sewage and farm animals [7]. These epidemi-
ological differences might be associated with use of
the glycopeptide avoparcin as a growth promoter
for food animals in some European countries.
However, this agent has not been approved for use
as an animal growth promoter in the USA, and has
not been used in Brazil since 1998 [4,7,8].
The first glycopeptide-resistant Enterococcus
strain isolated in Brazil was a strain of E. faecium
of the vanD genotype [9]. Later, several hospitals
located in Sa˜o Paulo and other Brazilian cities
reported outbreaks and isolated cases of infection
or colonisation with GRE [10,11]. Initially, most
reports were of E. faecium, but dissemination of
glycopeptide-resistant E. faecalis (GREf) has since
occurred in some Brazilian cities [11,12]. The
objective of the present study was to characterise
GREf isolates collected in Sa˜o Paulo hospitals and
to evaluate the dissemination of GREf clones
among Brazilian hospitals.
In total, 73 GREf isolates were collected from
patients hospitalised at the following Brazilian
hospitals: Hospital Sa˜o Paulo (n ¼ 36); Hospital do
Rim e Hipertensa˜o (n ¼ 10); Hospital Oswaldo
Cruz (n ¼ 7); Hospital 9 de Julho (n ¼ 6); Hospital
Bandeirantes (n ¼ 7); Hospital do Servidor Pu´blico
Estadual (n ¼ 4); Hospital Santa Paula (n ¼ 1);
Hospital Unimed Sorocaba (n ¼ 1); and Hospital
Santa Marcelina (n ¼ 1). One isolate ⁄patient was
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included in the study. The GREf strains were
isolated from the following body sites: urinary tract
(19.1%); blood (13.7%); soft tissues (6.8%); skin
(4.1%); lower respiratory tract (2.7%); upper res-
piratory tract (1.3%); anal swab (44%); and other
specimens (8.3%). The isolates were identified to
the species level with the conventional biochemical
tests described by Facklam et al. [13].
All samples were investigated by disk diffusion
[14] for resistance to ampicillin, teicoplanin,
vancomycin, gentamicin, streptomycin, chloram-
phenicol and doxycycline. Production of b-lacta-
mase was tested by the nitrocephin test (Becton
Dickinson, Sparks, MD, USA). MICs of vancomy-
cin, teicoplanin, ampicillin and linezolid were
determined by Etest (AB Biodisk, Solna, Sweden)
for isolates with vancomycin inhibition zones
£ 16 mm. Isolates were categorised according to
the National Committee for Clinical Laboratory
Standards (NCCLS) breakpoints [14]. ATCC
strains Staphylococcus aureus 29213 and E. faecalis
29212 were used as controls.
All strains were typed by pulsed-field gel
electrophoresis (PFGE). SmaI restriction digests
of total DNA were analysed on the CHEF-DRIII
system (Bio-Rad Laboratories, Richmond, CA,
USA) in 0.5· TBE buffer (89 mM Tris, 89 mM boric
acid, 2 mM EDTA) on an agarose 1% w ⁄ v gel.
Electrophoresis was for 23 h at 200 V, with a
switch interval ramped from 5 to 30 s. PFGE
patterns were considered identical if every band
was shared, similar if there were one to three
band differences, and different if there were four
or more band differences [15]. One isolate of
glycopeptide-susceptible E. faecalis was included
in each PFGE run as a control. Vancomycin
resistance genotypes were determined by PCR
with vanA- and vanB-specific primers [16,17]
selected from published gene sequences.
All isolates showed high-level resistance to
vancomycin and teicoplanin, which is character-
istic of the vanA phenotype. All isolates were
susceptible to linezolid and ampicillin, and
high-level resistance to streptomycin was not
detected in any isolate. In contrast, all isolates
showed high-level resistance to gentamicin. All
isolates were negative for b-lactamase produc-
tion.
All 73 isolates displayed a single major PFGE
pattern, A, with six subtypes (Table 1). The
glycopeptide-susceptible isolate had a completely
different PFGE pattern. The most prevalent sub-
type was A1, which was found in 51 (70%)
isolates from seven hospitals. The second most
common subtype was A2, which was detected in
18 (26%) isolates from five hospitals. All isolates,
except the negative control, were positive for
vanA by PCR, in agreement with the phenotypic
analysis.
GRE have emerged as an important cause of
nosocomial and community-acquired infections,
but were only recently described in South Amer-
ica [18]. However, since the first report, the
frequency of isolation of GRE has increased
significantly, especially in Brazil [11,12]. Treat-
ment of infections with GRE has been extremely
problematic, since these organisms are resistant to
multiple classes of antimicrobial agents. Although
the epidemic strain evaluated in the present study
was fully susceptible to ampicillin and linezolid,
it was fully resistant to gentamicin. Treatment of
severe systemic infections caused by these isolates
will therefore require use of streptomycin, a more
toxic aminoglycoside, in order to obtain syner-
gism.
Reis et al. [11] found several strains of vanco-
mycin-resistant enterococci showing identical or
similar PFGE patterns from different medical
Table 1. Distribution of PFGE pat-
terns of the 73 isolates according to
the medical centres evaluated
Hospital (total number of isolates)
Number of isolates of each subtype
A1 A2 A3 A4 A5 A6
Hospital do Rim e Hipertensa˜o (10) 6 4 – – – –
Hospital 9 Julho (6) 3 2 1 – – –
Hospital Bandeirantes (7) 5 2 – – – –
Hospital do Servidor Pu´blico
Estadual (4)
4 – – – – –
Hospital Oswaldo Cruz (7) 6 – – 1 – –
Hospital Santa Paula (1) – 1 – – – –
Hospital Unimed Sorocaba (1) 1 – – – – –
Hospital Sa˜o Paulo (36) 26 9 – – 1 –
Hospital Santa Marcelina (1) – – – – – 1
Total (73) 51 18 1 1 1 1
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centres in Sa˜o Paulo, Brazil, which strongly
suggests inter-hospital dissemination of this
pathogen. Other studies have documented spread
of a vancomycin-resistant Enterococcus clone
among hospitals [19–21]. In the present study,
molecular typing results indicated clonal dissem-
ination of GREf in all the participating centres.
The recognition of subtypes may reflect hospital-
specific evolution of the main clone. The absence
of a surveillance system for infected or colonised
patients upon hospital readmission in Brazil
might have contributed to this dissemination.
However, further epidemiological studies, as well
as studies on the use of antibiotics as animal
growth promoters, are necessary to evaluate the
precise mode of dissemination of glycopeptide
resistance among E. faecalis isolates in Brazil.
This report emphasises the need for appropriate
infection control measures in hospitals and pub-
lic-health communities. The findings also raise
concerns about rapid dissemination of this patho-
gen throughout other Brazilian hospitals.
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